Telehealth companies, health insurers and pharmaceutical manufacturers are playing the blame game amid a shortage of popular weight loss drugs.
Wegovy manufacturer Novo Nordisk said in May shortages of certain doses of the weight loss drug are expected to persist through September. The shortage of weight loss medications known as glucagon-like peptide agnostics, or GLP-1s, also includes Novo Nordisk’s diabetes drug Ozempic and Eli…